KBC Group NV Lowers Position in Bruker Corporation $BRKR

KBC Group NV lessened its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 5.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 42,486 shares of the medical research company’s stock after selling 2,229 shares during the period. KBC Group NV’s holdings in Bruker were worth $1,750,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its position in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after buying an additional 487 shares in the last quarter. Huntington National Bank raised its stake in Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after acquiring an additional 645 shares during the period. Spire Wealth Management purchased a new stake in shares of Bruker in the second quarter worth $32,000. Caitong International Asset Management Co. Ltd raised its position in shares of Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 745 shares during the period. Finally, Parallel Advisors LLC raised its position in shares of Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 347 shares during the period. Institutional investors own 79.52% of the company’s stock.

Insiders Place Their Bets

In related news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares of the company’s stock, valued at approximately $581,016. This trade represents a 16.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 27.30% of the company’s stock.

Bruker Stock Performance

NASDAQ BRKR opened at $41.62 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.64. The business has a 50 day simple moving average of $36.04 and a two-hundred day simple moving average of $37.15. The stock has a market capitalization of $6.32 billion, a PE ratio of 80.04, a P/E/G ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.12. The business had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The company’s revenue for the quarter was down .5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, research analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is -125.00%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. TD Cowen increased their price target on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a research note on Tuesday, November 4th. Citigroup dropped their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research note on Monday, August 4th. Stifel Nicolaus set a $40.00 target price on Bruker and gave the stock a “hold” rating in a research report on Tuesday, August 5th. Weiss Ratings reissued a “sell (d)” rating on shares of Bruker in a report on Thursday. Finally, Cowen restated a “hold” rating on shares of Bruker in a research note on Tuesday, November 4th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $48.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.